• In 2022, revenue fell 24% YoY to $7.1M, but beat our estimate by 8%. Revenue declined as the company discontinued in-house manufacturing, and production for third parties. As a result, this company was able to lower G&A expenses by 35% YoY, and improve EBITDA from -$14M to -$9M vs our estimate of -$11M.
          • This report is currently available to premium subscribers – Free subscribers will gain access on Mar 15th, 2022 Join as a FREE member and get our research report delivered straight to your inbox, with a seven-day delay

Visit Elixinol Wellness Limited page for more research, discussion boards and to like, and share.

Are you enjoying the highlights?

Discover the company's fair value estimate from our certified analysts, identify potential risks, and explore exciting upcoming catalysts in our detailed report.

Already a member? Sign In